$Pfizer (PFE.US)$ IDEAYA Biosciences (IDYA) said Thursday th...
$Pfizer (PFE.US)$ IDEAYA Biosciences (IDYA) said Thursday that it has completed its targeted full enrollment of 435 patients in the phase 2/3 trial evaluating darovasertib in combination with Pfizer's (PFE) crizotinib for the treatment of metastatic uveal melanoma, a form of ocular cancer.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
